Standard Chartered second-quarter profit rises 54%, unveils US$1.3 billion share buy-back


Standard Chartered said on Thursday its second-quarter net profit rose 54 per cent from a year earlier, driven by strong growth in cross-border trades and wealth businesses that offset rising bad debt, as it unveiled a US$1.3 billion share repurchase plan.

Net profit for the April-to-June quarter rose to US$1.8 billion, or 72.5 US cents a share, from US$1.17 billion a year earlier, the bank said in a filing to the Hong Kong stock exchange. The result exceeded an analysts’ consensus estimate of US$1.33 billion that was compiled by the bank.

The London-based bank, which generates most of its business from Asia, said its pre-tax underlying profit for the period rose 34 per cent from a year earlier to US$2.4 billion, beating a consensus estimate of US$1.9 billion.

For the first half, net profit rose 41 per cent to US$3.07 billion from US$2.17 billion a year earlier. Analysts expected a profit of US$2.82 billion. The bank announced an interim dividend of 12.3 US cents a share, up 27 per cent from a year earlier.

Standard Chartered CEO Bill Winters. Photo: Jonathan Wong
Standard Chartered CEO Bill Winters. Photo: Jonathan Wong

“Our strong first-half performance reflects continued successful execution of our strategy, through our focus on cross-border and affluent banking,” CEO Bill Winters said in the statement.

“Through our unique network across Asia, Africa and the Middle East, we offer our clients the means to navigate volatile external conditions. We are performing well, while keeping a tight grip on costs, credit risk and capital.”

  • Related Posts

    JD.com posts first quarterly loss in nearly four years as delivery battle takes toll

    Chinese e-commerce giant JD.com reported a 2.7 billion yuan (US$392 million) loss in the fourth quarter and a halving of annual profit amid an ongoing food delivery battle it ignited…

    Continue reading
    China and Hong Kong should relax biotech listing rules, venture capitalist says

    Mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalise on renewed foreign interest in the healthcare sector, venture…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *